"The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.
Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is"...
Although the precise mechanism of anthralin's anti-psoriatic action is not fully understood, in vitro evidence suggests that its antimitotic effect results from inhibition of DNA synthesis. Additionally, the chemically reducing properties of anthralin may upset oxidative metabolic processes, providing a further slowing down of epidermal mitosis. Absorption in man has not been finally determined, but in a limited clinical study of anthralin cream, no traces of anthraquinone metabolites were detected in the urine of subjects treated; however, caution is advised in patients with renal disease.
Last reviewed on RxList: 5/26/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Dritho-Scalp Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.